{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:35Z","timestamp":1793176775865,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacl.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:11:25Z","timestamp":1786518685000},"page":"2119-2127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of olezarsen in patients with vs without baseline fibrate use"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9637-823X","authenticated-orcid":false,"given":"Annabel Z.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-692X","authenticated-orcid":false,"given":"Thomas A.","family":"Prohaska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-264X","authenticated-orcid":false,"given":"Erica L.","family":"Goodrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8231-3611","authenticated-orcid":false,"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Zimerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe A.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Mi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-2459","authenticated-orcid":false,"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Sequeira","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5592-6199","authenticated-orcid":false,"given":"Jorge","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Dzupina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-7675","authenticated-orcid":false,"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-4617","authenticated-orcid":false,"given":"Nicholas A.","family":"Marston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-7606","authenticated-orcid":false,"given":"Brian A.","family":"Bergmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacl.2026.08.001_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jacl.2018.11.008","article-title":"Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey","volume":"13","author":"Fan","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.001_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.001_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"10.1016\/j.jacl.2026.08.001_bib4","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.001_bib5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacl.2026.08.001_bib6","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.001_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.001_bib8","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"42","key":"10.1016\/j.jacl.2026.08.001_bib9","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.08.001_bib10","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001457","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacl.2026.08.001_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacl.2026.08.001_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jacl.2026.08.001_bib13","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with olezarsen in moderate hypertriglyceridemia","volume":"393","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacl.2026.08.001_bib14","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.08.001_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ahj.2025.02.022","article-title":"Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: rationale and design of the Essence\u2013TIMI 73b trial","volume":"286","author":"Bergmark","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2026.08.001_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2025.03.003","article-title":"Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia","volume":"286","author":"Marston","year":"2025","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.001_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/jcem.86.3.7304","article-title":"Diabetic dyslipidemia: causes and consequences","volume":"86","author":"Goldberg","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.001_bib18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:27:22Z","timestamp":1793176042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1933287426004757"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of olezarsen in patients with vs without baseline fibrate use","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}